224 related articles for article (PubMed ID: 12756208)
1. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Drug Metab Dispos; 2003 Jun; 31(6):755-61. PubMed ID: 12756208
[TBL] [Abstract][Full Text] [Related]
2. Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.
Kamdem LK; Meineke I; Koch I; Zanger UM; Brockmöller J; Wojnowski L
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jul; 370(1):71-7. PubMed ID: 15232676
[TBL] [Abstract][Full Text] [Related]
3. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
4. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
[TBL] [Abstract][Full Text] [Related]
5. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Saito T; Parkinson A; Nakagawa K; Kamataki T
Xenobiotica; 2005 Jan; 35(1):69-83. PubMed ID: 15788369
[TBL] [Abstract][Full Text] [Related]
6. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype.
Lamba J; Strom S; Venkataramanan R; Thummel KE; Lin YS; Liu W; Cheng C; Lamba V; Watkins PB; Schuetz E
Clin Pharmacol Ther; 2006 Apr; 79(4):325-38. PubMed ID: 16580901
[TBL] [Abstract][Full Text] [Related]
7. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
8. Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
[TBL] [Abstract][Full Text] [Related]
9. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR).
Burk O; Koch I; Raucy J; Hustert E; Eichelbaum M; Brockmöller J; Zanger UM; Wojnowski L
J Biol Chem; 2004 Sep; 279(37):38379-85. PubMed ID: 15252010
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.
Cerveny L; Svecova L; Anzenbacherova E; Vrzal R; Staud F; Dvorak Z; Ulrichova J; Anzenbacher P; Pavek P
Drug Metab Dispos; 2007 Jul; 35(7):1032-41. PubMed ID: 17392393
[TBL] [Abstract][Full Text] [Related]
11. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
Foo WY; Tay HY; Chan EC; Lau AJ
Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
[TBL] [Abstract][Full Text] [Related]
12. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver.
Iwahori T; Matsuura T; Maehashi H; Sugo K; Saito M; Hosokawa M; Chiba K; Masaki T; Aizaki H; Ohkawa K; Suzuki T
Hepatology; 2003 Mar; 37(3):665-73. PubMed ID: 12601364
[TBL] [Abstract][Full Text] [Related]
13. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
Lin YS; Dowling AL; Quigley SD; Farin FM; Zhang J; Lamba J; Schuetz EG; Thummel KE
Mol Pharmacol; 2002 Jul; 62(1):162-72. PubMed ID: 12065767
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.
Gashaw I; Kirchheiner J; Goldammer M; Bauer S; Seidemann J; Zoller K; Mrozikiewicz PM; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Nov; 74(5):448-57. PubMed ID: 14586385
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.
Klees TM; Sheffels P; Thummel KE; Kharasch ED
Anesthesiology; 2005 Mar; 102(3):550-6. PubMed ID: 15731592
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers.
Hakkola J; Raunio H; Purkunen R; Saarikoski S; Vähäkangas K; Pelkonen O; Edwards RJ; Boobis AR; Pasanen M
Biol Neonate; 2001; 80(3):193-201. PubMed ID: 11585982
[TBL] [Abstract][Full Text] [Related]
17. Genetic predictors of interindividual variability in hepatic CYP3A4 expression.
Lamba V; Panetta JC; Strom S; Schuetz EG
J Pharmacol Exp Ther; 2010 Mar; 332(3):1088-99. PubMed ID: 19934400
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
19. Variability of CYP3A7 expression in human fetal liver.
Leeder JS; Gaedigk R; Marcucci KA; Gaedigk A; Vyhlidal CA; Schindel BP; Pearce RE
J Pharmacol Exp Ther; 2005 Aug; 314(2):626-35. PubMed ID: 15845858
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
